Therapeutic vaccines for leishmaniasis

Area of Science:

• Immunology
• Infectious Diseases
• Vaccinology

Background:

• Current treatments for leishmaniasis, particularly cutaneous leishmaniasis (CL), rely on antimonate derivatives with significant safety concerns and variable efficacy.
• Effective treatments for CL caused by Leishmania tropica and Leishmania braziliensis remain a challenge.
• No prophylactic vaccine is currently available for any form of leishmaniasis.

Purpose of the Study:

• To review prophylactic vaccines and discuss immunotherapy strategies for leishmaniasis.
• To focus on human trials of vaccines that have reached clinical application.

Main Methods:

• Review of existing literature on prophylactic vaccines and immunotherapy for leishmaniasis.
• Emphasis on human trials and vaccines that have progressed to human testing.
• Exclusion of experimental vaccines not yet tested in humans.

Main Results:

• First and second-generation immunotherapy vaccine trials have demonstrated encouraging outcomes for CL.
• Immunotherapy is a viable treatment option for various disorders, characterized by low cost and minimal side effects.

Conclusions:

• Immunotherapy presents a valuable alternative for infectious diseases, especially when chemotherapy faces challenges.
• Further investigation is required to identify immunological markers for cure and protection in leishmaniasis.
• Development of standardized crude Leishmania vaccines and appropriate adjuvants is crucial for successful anti-leishmaniasis vaccine strategies.